Drug Type Prophylactic vaccine |
Synonyms GBP510 adjuvanted with AS03(SK Bioscience), Skycovion COVID-19 vaccine, GSK 4382371A + [2] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (29 Jun 2022), |
Regulation- |
Start Date09 Dec 2022 |
Sponsor / Collaborator |
Start Date24 Jan 2022 |
Sponsor / Collaborator |
Start Date30 Aug 2021 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | South Korea | 29 Jun 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Severe Acute Respiratory Syndrome | Phase 3 | Colombia | 09 Dec 2022 | |
Severe Acute Respiratory Syndrome | Phase 3 | Colombia | 09 Dec 2022 | |
Severe Acute Respiratory Syndrome | Phase 3 | Nepal | 09 Dec 2022 | |
Severe Acute Respiratory Syndrome | Phase 3 | Nepal | 09 Dec 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |